On the stock market since 2021, it operates in the world of health and science. It has 103 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 28% below its peak. The market has trimmed its expectations for the company.
There is $276.1M in the vault; even if every debt were paid off, $228.9M would remain.
The average analyst price target is $22.50 — 28% above today’s price.
A loss of $124.5M against $0 in annual sales.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
On our five-subject report card, ERAS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ERAS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (52/100) says the stock isn’t cheap.